Tratamiento de la neumonía del adulto adquirida en la comunidad

Appropriate antibiotic treatment reduces the duration of symptoms associated to pneumonia, the risk of complications and mortality. In most cases, it is not possible to identify the etiologic agent so antibiotic treatment is empirically prescribed. In Chile, one third of Streptococcus pneumoniae str...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Díaz F,Alejandro, Labarca L,Jaime, Pérez C,Carlos, Ruiz C,Mauricio, Wolff R,Marcelo
Lenguaje:Spanish / Castilian
Publicado: Sociedad Chilena de Infectología 2005
Materias:
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182005000400008
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0716-10182005000400008
record_format dspace
spelling oai:scielo:S0716-101820050004000082005-12-06Tratamiento de la neumonía del adulto adquirida en la comunidadDíaz F,AlejandroLabarca L,JaimePérez C,CarlosRuiz C,MauricioWolff R,Marcelo neumonía tratamiento manejo de la enfermedad antibióticos Appropriate antibiotic treatment reduces the duration of symptoms associated to pneumonia, the risk of complications and mortality. In most cases, it is not possible to identify the etiologic agent so antibiotic treatment is empirically prescribed. In Chile, one third of Streptococcus pneumoniae strain isolates has diminished susceptibility to penicillin; in-vitro erythromycin resistance is about 10-15% and cefotaxime resistance 2-10%. It is recommended to classify patients with community acquired pneumonia in four risk categories: Group 1: patients under 65 years without co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin 1 g TID, 7 days. Group 2: patients over 65 years and / or co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin/clavulanate 500/125 mg TID or 875/125 mg BID, or cefuroxime 500 mg BID, 7 days. Group 3: patients admitted to general wards with criteria of moderate severity. Treatment: ceftriaxone 1-2 g once a day or cefotaxime 1 g TID, IV, 7-10 days. Group 4: patients with severe CAP that must be interned into ICU. Treatment: ceftriaxone 2 g once a day or cefotaxime 1 g TID, IV, associated to erythromycin 500 QID, levofloxacin 500-1.000 mg once a day, or moxifloxacin 400 mg/once a day, IV, 10-14 days. In the presence of allergy to or treatment failure with betalactam drugs and/or positive serology for Mycoplasma, Chlamydia or Legionella sp it is recommended to add: erythromycin 500 mg QID, IV or oral, oral clarithromycin 500 mg BID, or oral azythromycin 500 mg once a dayinfo:eu-repo/semantics/openAccessSociedad Chilena de InfectologíaRevista chilena de infectología v.22 suppl.1 20052005-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182005000400008es10.4067/S0716-10182005000400008
institution Scielo Chile
collection Scielo Chile
language Spanish / Castilian
topic neumonía
tratamiento
manejo de la enfermedad
antibióticos
spellingShingle neumonía
tratamiento
manejo de la enfermedad
antibióticos
Díaz F,Alejandro
Labarca L,Jaime
Pérez C,Carlos
Ruiz C,Mauricio
Wolff R,Marcelo
Tratamiento de la neumonía del adulto adquirida en la comunidad
description Appropriate antibiotic treatment reduces the duration of symptoms associated to pneumonia, the risk of complications and mortality. In most cases, it is not possible to identify the etiologic agent so antibiotic treatment is empirically prescribed. In Chile, one third of Streptococcus pneumoniae strain isolates has diminished susceptibility to penicillin; in-vitro erythromycin resistance is about 10-15% and cefotaxime resistance 2-10%. It is recommended to classify patients with community acquired pneumonia in four risk categories: Group 1: patients under 65 years without co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin 1 g TID, 7 days. Group 2: patients over 65 years and / or co-morbidities, in ambulatory attendance. Treatment: oral amoxicillin/clavulanate 500/125 mg TID or 875/125 mg BID, or cefuroxime 500 mg BID, 7 days. Group 3: patients admitted to general wards with criteria of moderate severity. Treatment: ceftriaxone 1-2 g once a day or cefotaxime 1 g TID, IV, 7-10 days. Group 4: patients with severe CAP that must be interned into ICU. Treatment: ceftriaxone 2 g once a day or cefotaxime 1 g TID, IV, associated to erythromycin 500 QID, levofloxacin 500-1.000 mg once a day, or moxifloxacin 400 mg/once a day, IV, 10-14 days. In the presence of allergy to or treatment failure with betalactam drugs and/or positive serology for Mycoplasma, Chlamydia or Legionella sp it is recommended to add: erythromycin 500 mg QID, IV or oral, oral clarithromycin 500 mg BID, or oral azythromycin 500 mg once a day
author Díaz F,Alejandro
Labarca L,Jaime
Pérez C,Carlos
Ruiz C,Mauricio
Wolff R,Marcelo
author_facet Díaz F,Alejandro
Labarca L,Jaime
Pérez C,Carlos
Ruiz C,Mauricio
Wolff R,Marcelo
author_sort Díaz F,Alejandro
title Tratamiento de la neumonía del adulto adquirida en la comunidad
title_short Tratamiento de la neumonía del adulto adquirida en la comunidad
title_full Tratamiento de la neumonía del adulto adquirida en la comunidad
title_fullStr Tratamiento de la neumonía del adulto adquirida en la comunidad
title_full_unstemmed Tratamiento de la neumonía del adulto adquirida en la comunidad
title_sort tratamiento de la neumonía del adulto adquirida en la comunidad
publisher Sociedad Chilena de Infectología
publishDate 2005
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182005000400008
work_keys_str_mv AT diazfalejandro tratamientodelaneumoniadeladultoadquiridaenlacomunidad
AT labarcaljaime tratamientodelaneumoniadeladultoadquiridaenlacomunidad
AT perezccarlos tratamientodelaneumoniadeladultoadquiridaenlacomunidad
AT ruizcmauricio tratamientodelaneumoniadeladultoadquiridaenlacomunidad
AT wolffrmarcelo tratamientodelaneumoniadeladultoadquiridaenlacomunidad
_version_ 1718440087779278848